This article was originally published in The Gray Sheet
Developer of the Solo miniature insulin dispensing patch pump, which is 92% owned by diversified conglomerate Elron, could be sold for up to $213 million, including milestone payments, based on a "non-binding indication of interest" from an un-named third party, Elron says Oct. 26. But a Medingo deal would be subject to signing of a definitive agreement, and currently "there is no assurance of the occurrence, timing or terms of any such transaction," the firm says
You may also be interested in...
Firm is ramping up production for expected 2012 launch of the Solo pump.
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.